Maharashtra FDA bans Coldrif Syrup after child deaths in Madhya Pradesh and Rajasthan.
Syrup made by Sarron Pharma in Tamil Nadu found contaminated with toxic Diethylene Glycol (DEG).
Pune FDA teams begin seizure drives; citizens urged to report remaining stock.
Pune, 6th October 2025: The Food and Drug Administration (FDA) of Maharashtra has imposed an urgent prohibition on the sale and usage of Coldrif Syrup, a cough syrup allegedly associated with the deaths of multiple children in Madhya Pradesh and Rajasthan. The FDA has urged residents and pharmacists throughout the state to cease its use and promptly report any existing inventory.
State Drug Controller D. R. Gahane reported that Coldrif Syrup, containing Phenylephrine Hydrochloride and Chlorpheniramine Maleate, with batch number SR-13, was produced in May 2025 and is due to expire in April 2027. This syrup is manufactured by Sarron Pharma, located in Kanchipuram, Tamil Nadu. Initial testing has revealed the presence of Diethylene Glycol (DEG), a hazardous chemical that can lead to serious poisoning and potentially fatal outcomes.
Following this alert, FDA teams in Pune and other districts have started inspecting medical stores and distributors. Officials have been instructed to seize any found stock and halt its sale or distribution. Furthermore, the public has been cautioned against using this syrup under any circumstances.
The FDA has collaborated with Tamil Nadu's drug regulators to track Sarron Pharma's distribution network and determine if the tainted batch was distributed to other regions of India. Officials have promised that precautionary steps are being implemented to prevent additional damage.
People who have purchased the syrup or encountered it in circulation are encouraged to inform local drug inspectors or contact the FDA helpline at 1800 222 365, or email jchq.fda-mah@nic.in. Officials have urged the public to remain alert and help in removing this dangerous medicine from the market.